May 5 (Reuters) – U.S. Food and Drug Administration Commissioner Dr. Marty Makary on Tuesday defended the agency’s decision to not approve Replimune’s drug for advanced skin cancer.
“If you read our what we call our complete response letter, you will see the details of the FDA logic,” Makary said in an interview on CNBC.
Replimune shares were down 5% in morning trading.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shinjini Ganguli)
Brought to you by www.srnnews.com
Bear attack injures two hikers in Yellowstone National Park
The Media Line: University of Michigan Apologizes After Commencement Speech Praises Pro-Palestinian Activists